IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5453-5462

  Kagami, Shinji ^a   Rizzo, Heather L ^a   Kurtz, Stephen E ^a   Miller, Lloyd S ^b   Blauvelt, Andrew ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 17A; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CYTOKINE PRODUCTION; EPIDERMIS HYPERPLASIA; FUNGUS IMMUNITY; GENE EXPRESSION; HEALING IMPAIRMENT; HISTOPATHOLOGY; HOST RESISTANCE; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; TH17 CELL; WOUND HEALING; ANIMAL; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; SKIN CANDIDIASIS;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS, CUTANEOUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN;

EID: 78149491862     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001153     Document Type: Article

References (41)

1. Holland, S. M., and D. C. Vinh. 2009. Yeast infections-human genetics on the rise. N. Engl. J. Med. 361:1798-1801.
2. Ramos-E-Silva, M., C. M. Lima, R. C. Schechtman, B. M. Trope, and S. Carneiro. 2010. Superficial mycoses in immunodepressed patients (AIDS). Clin. Dermatol. 28:217-225.
3. Marr, K. A. 2010. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr. Opin. Oncol. 22:138-142.
4. Zilberberg, M. D., and A. F. Shorr. 2009. Fungal infections in the ICU. Infect. Dis. Clin. North Am. 23:625-642.
5. Soysa, N. S., L. P. Samaranayake, and A. N. Ellepola. 2006. Diabetes mellitus as a contributory factor in oral candidosis. Diabet. Med. 23:455-459.
6. Netea, M. G., C. A. Van der Graaf, A. G. Vonk, I. Verschueren, J. W. Van der Meer, and B. J. Kullberg. 2002. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 185:1483-1489.
7. van de Veerdonk, F. L., R. J. Marijnissen, B. J. Kullberg, H. J. Koenen, S. C. Cheng, I. Joosten, W. B. van den Berg, D. L. Williams, J. W. van der Meer, L. A. Joosten, and M. G. Netea. 2009. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 5:329-340.
8. LeibundGut-Landmann, S., O. Gross, M. J. Robinson, F. Osorio, E. C. Slack, S. V. Tsoni, E. Schweighoffer, V. Tybulewicz, G. D. Brown, J. Ruland, and C. Reis e Sousa. 2007. Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8:630-638.
9. Robinson, M. J., F. Osorio, M. Rosas, R. P. Freitas, E. Schweighoffer, O. Gross, J. S. Verbeek, J. Ruland, V. Tybulewicz, G. D. Brown, et al. 2009. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J. Exp. Med. 206:2037-2051.
10. Richardson, M., and R. Rautemaa. 2009. How the host fights against Candida infections. Front. Biosci. 14:4363-4375.
11. Romani, L., S. Mocci, C. Bietta, L. Lanfaloni, P. Puccetti, and F. Bistoni. 1991. Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect. Immun. 59:4647-4654.
12. Fidel, P. L., Jr., M. E. Lynch, and J. D. Sobel. 1993. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect. Immun. 61:4202-4207.
13. Gozalbo, D., and M. L. Gil. 2009. IFN-gamma in Candida albicans infections. Front. Biosci. 14:1970-1978.
14. d'Ostiani, C. F., G. Del Sero, A. Bacci, C. Montagnoli, A. Spreca, A. Mencacci, P. Ricciardi-Castagnoli, and L. Romani. 2000. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J. Exp. Med. 191:1661-1674.
15. Cenci, E., A. Mencacci, G. Del Sero, C. F. d'Ostiani, P. Mosci, A. Bacci, C. Montagnoli, M. Kopf, and L. Romani. 1998. IFN-gamma is required for IL-12 responsiveness in mice with Candida albicans infection. J. Immunol. 161:3543-3550.
16. Matsuzaki, G., and M. Umemura. 2007. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol. Immunol. 51:1139-1147.
17. Conti, H. R., F. Shen, N. Nayyar, E. Stocum, J. N. Sun, M. J. Lindemann, A. W. Ho, J. H. Hai, J. J. Yu, J. W. Jung, et al. 2009. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206:299-311.
18. Eyerich, K., S. Foerster, S. Rombold, H. P. Seidl, H. Behrendt, H. Hofmann, J. Ring, and C. Traidl-Hoffmann. 2008. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J. Invest. Dermatol. 128:2640-2645.
19. Miossec, P., T. Korn, and V. K. Kuchroo. 2009. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361:888-898.
20. Ma, C. S., G. Y. Chew, N. Simpson, A. Priyadarshi, M. Wong, B. Grimbacher, D. A. Fulcher, S. G. Tangye, and M. C. Cook. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205:1551-1557.
21. Milner, J. D., J. M. Brenchley, A. Laurence, A. F. Freeman, B. J. Hill, K. M. Elias, Y. Kanno, C. Spalding, H. Z. Elloumi, M. L. Paulson, et al. 2008. Impaired T (H) 17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773-776.
22. Minegishi, Y. 2009. Hyper-IgE syndrome. Curr. Opin. Immunol. 21:487-492.
23. Ferwerda, B., G. Ferwerda, T. S. Plantinga, J. A. Willment, A. B. van Spriel, H. Venselaar, C. C. Elbers, M. D. Johnson, A. Cambi, C. Huysamen, et al. 2009. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361:1760-1767.
24. Glocker, E. O., A. Hennigs, M. Nabavi, A. A. Schäffer, C. Woellner, U. Salzer, D. Pfeifer, H. Veelken, K. Warnatz, F. Tahami, et al. 2009. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361:1727-1735.
25. Nakae, S., Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, and Y. Iwakura. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17:375-387.
26. Zheng, Y., D. M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang. 2007. Interleukin-22, a T (H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648-651.
27. Ghilardi, N., N. Kljavin, Q. Chen, S. Lucas, A. L. Gurney, and F. J. De Sauvage. 2004. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J. Immunol. 172:2827-2833.
28. Grimbacher, B., S. M. Holland, J. I. Gallin, F. Greenberg, S. C. Hill, H. L. Malech, J. A. Miller, A. C. O'Connell, and J. M. Puck. 1999. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder. N. Engl. J. Med. 340:692-702.
29. Renner, E. D., S. Rylaarsdam, S. Anover-Sombke, A. L. Rack, J. Reichenbach, J. C. Carey, Q. Zhu, A. F. Jansson, J. Barboza, L. F. Schimke, et al. 2008. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T (H) 17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol. 122:181-187.
30. Brenchley, J. M., M. Paiardini, K. S. Knox, A. I. Asher, B. Cervasi, T. E. Asher, P. Scheinberg, D. A. Price, C. A. Hage, L. M. Kholi, et al. 2008. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112:2826-2835.
31. Cho, J. S., E. M. Pietras, N. C. Garcia, R. I. Ramos, D. M. Farzam, H. R. Monroe, J. E. Magorien, A. Blauvelt, J. K. Kolls, A. L. Cheung, et al. 2010. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 120:1762-1773.
32. Shalom-Barak, T., J. Quach, and M. Lotz. 1998. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogenactivated protein kinases and NF-kappaB. J. Biol. Chem. 273:27467-27473.
33. Ley, K., E. Smith, and M. A. Stark. 2006. IL-17A-producing neutrophilregulatory Tn lymphocytes. Immunol. Res. 34:229-242.
34. Liang, S. C., A. J. Long, F. Bennett, M. J. Whitters, R. Karim, M. Collins, S. J. Goldman, K. Dunussi-Joannopoulos, C. M. Williams, J. F. Wright, and L. A. Fouser. 2007. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J. Immunol. 179:7791-7799.
35. von Vietinghoff, S., and K. Ley. 2009. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J. Immunol. 183:865-873.
36. Huang, W., L. Na, P. L. Fidel, and P. Schwarzenberger. 2004. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J. Infect. Dis. 190:624-631.
37. Caruso, R., E. Botti, M. Sarra, M. Esposito, C. Stolfi, L. Diluvio, M. L. Giustizieri, V. Pacciani, A. Mazzotta, E. Campione, et al. 2009. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat. Med. 15:1013-1015.
38. Sa, S. M., P. A. Valdez, J. Wu, K. Jung, F. Zhong, L. Hall, I. Kasman, J. Winer, Z. Modrusan, D. M. Danilenko, and W. Ouyang. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178:2229-2240.
39. Chan, J. R., W. Blumenschein, E. Murphy, C. Diveu, M. Wiekowski, S. Abbondanzo, L. Lucian, R. Geissler, S. Brodie, A. B. Kimball, et al. 2006. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203:2577-2587.
40. Leonardi, C. L., A. B. Kimball, K. A. Papp, N. Yeilding, C. Guzzo, Y. Wang, S. Li, L. T. Dooley, K. B. Gordon; PHOENIX 1 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665-1674.
41. Papp, K. A., R. G. Langley, M. Lebwohl, G. G. Krueger, P. Szapary, N. Yeilding, C. Guzzo, M. C. Hsu, Y. Wang, S. Li, et al; PHOENIX 2 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675-1684.